The Foundation of the Consortium of Multiple Sclerosis Centers (FCMSC) was gifted $100,000 by EMD Serono for its nursing scholarship fund.

Plasma exchange therapy is effective for severe relapses in MS patients who respond inadequately to standard corticosteroids, ...

A sublingual formulation of cladribine showed comparable pharmacological properties to its name brand counterpart, Mavenclad.

Anti-CD20 therapies like Ocrevus and rituximab may be ineffective at slowing disability progression in PPMS patients, per a ...

Cionic is partnering with a veteran-owned business to improve access to its Neural Sleeve for improving patients' walking ...

I drive a wheelchair now. Mine tilts and reclines, so it’s a bit heavier than most. It’s not a car, but there’s a certain amount of responsibility that goes with it because like any vehicle, it too is ...

A sublingual formulation of cladribine, which is the active ingredient of the approved oral treatment Mavenclad, in relapsing multiple sclerosis (MS), showed comparable pharmacological properties ...